Across its top 20 institutional holders, TVTX's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 8/100, avg. turnover score 35/100).
Quarterly Activity
Recent Activity
+$1.9B
Total Buy Value
$2.0B
Total Sell Value
New buy41
Trim94
Add93
Sold out61
134
Net Buyers
155
Net Sellers
Smart Money Convergence
TVTX does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
2
Filings (90d)
$725K
Total Est. Value
15K shares
Planned Shares
Last Filed 2026-06-12
Filer
Title/Relationship
Filing Date
Planned Shares
Est. Value
Baynes Roy D.
Director
2026-06-12
5K shares
$225K
Coughlin Timothy
Director
2026-06-12
10K shares
$500K
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
1
Filings (14d)
Data as of 2026-07-09
2026-07-09
Sandra Calvin, Chief Accounting Officer of Travere Therapeutics, notified the company she plans to retire in February 2027 after the annual report is filed. Vice President and Controller John Torell is expected to succeed her as CAO, and the board will appoint him before her departure to ensure a smooth transition.
Who are the top institutional investors holding TRAVERE THERAPEUTICS INC (TVTX)?
Major stakeholders currently include Janus Henderson Group PLC ($339.2M), FMR LLC ($325.9M), BlackRock, Inc. ($231.5M). Based on the latest 13F filings, there are a total of 261 tracked investment funds and institutions maintaining positions in TVTX.
What is the overall institutional sentiment toward TVTX recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $910.4M, driven by 134 managers accumulating shares while 155 reduced their exposure.
Which institutions have been selling or reducing their TVTX positions?
In the latest period, 94 funds trimmed their holdings, and 61 managers completely exited their positions. The aggregate reported sell value was $2.0B.
Are there any notable investors adding TVTX to their portfolios?
Yes, buying activity remains notable. 41 institutions opened new positions in {ticker}, and 93 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.9B.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter